We are live on ! Find out more
BCM

BML Capital Management Portfolio holdings

AUM $156M
1-Year Est. Return 129.82%
This Fund
S&P 500
This Quarter Est. Return
-9.94%
1 Year Est. Return
+129.82%
3 Year Est. Return
+394.84%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$140M
AUM Growth
-$11.5M
Cap. Flow
+$3.83M
Cap. Flow %
2.73%
Top 10 Hldgs %
83.64%
Holding
35
New
3
Increased
10
Reduced
4
Closed
7

Top Buys

Rank Stock Value
1
ADVM
Adverum Biotechnologies
ADVM
+$10.5M
2
ACRS icon
Aclaris Therapeutics
ACRS
+$4.22M
3
AVIR icon
Atea Pharmaceuticals
AVIR
+$3.13M
4
TECX
Tectonic Therapeutic
TECX
+$2.12M
5
VNDA icon
Vanda Pharmaceuticals
VNDA
+$2.06M

Top Sells

Rank Stock Value
1
CYT
Cyteir Therapeutics, Inc. Common Stock
CYT
+$11M
2
CLYM
Climb Bio
CLYM
+$6.01M
3
DSGN icon
Design Therapeutics
DSGN
+$1.78M
4
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
+$1.33M
5
ORKA
Oruka Therapeutics
ORKA
+$1.24M

Sector Composition

Rank Sector Weight
1 Healthcare 63.54%
2 Technology 1.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NXTC icon
26
NextCure
NXTC
$21.4M
$440K 0.31%
23,039
-2,500
-10% -$48.6K
KLRS
27
Kalaris Therapeutics
KLRS
$84.9M
$436K 0.31%
26,221
+17,505
+201% +$309K
TLIS
28
DELISTED
Talis Biomedical Corporation Common Stock
TLIS
$370K 0.26%
42,743
– –
ANF icon
29
PUT
Abercrombie & Fitch
ANF
$4.38B
– –
-100
Closed -$470K
ELVN icon
30
Enliven Therapeutics
ELVN
$3.86B
– –
-50,100
Closed -$881K
QTTB icon
31
Q32 Bio
QTTB
$455M
– –
-24,894
Closed -$424K
ORKA
32
Oruka Therapeutics
ORKA
$5.53B
– –
-58,911
Closed -$1.24M
CLYM
33
Climb Bio
CLYM
$745M
– –
-2,193,742
Closed -$6.01M
KNTE
34
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
– –
-498,851
Closed -$1.33M
CYT
35
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
– –
-3,654,053
Closed -$11M
1
2

Similar funds

AIS
Accredited Investor Services St. Cloud, Minnesota $156M AUM 21.61% 1-Year Est. Return
BWM
BNB Wealth Management Silver Spring, Maryland $156M AUM
CFG
Cornerstone Financial Group Omaha, Nebraska $156M AUM 12% 1-Year Est. Return
IWA
Invera Wealth Advisors Bend, Oregon $156M AUM 22.76% 1-Year Est. Return
PFO
Pioneer Family Office North Miami Beach, Florida $156M AUM
BCM
Bluefin Capital Management New York $156M AUM 18.47% 1-Year Est. Return
PMSA
Patrick M. Sweeney & Associates Libertyville, Illinois $156M AUM 19.16% 1-Year Est. Return
GSWA
Good Steward Wealth Advisors Clarksville, Tennessee $156M AUM 13.06% 1-Year Est. Return

BML Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, BML Capital Management held 35 positions worth $140M, down 7.6% from $152M the previous quarter. Its ten largest holdings account for 84% of the portfolio.

BML Capital Management's Q2 2024 filing shows 3 new, 10 increased, 4 reduced and 7 closed positions. Its largest new stake was Vanda Pharmaceuticals: 398,280 shares worth $2.25M. The largest sale was Cyteir Therapeutics, Inc. Common Stock, an estimated $11M.

By sector, the portfolio is most concentrated in Healthcare at 64% of assets, down from 67% a quarter earlier, followed by Technology.

  • BML Capital Management's largest Q2 2024 buy was Vanda Pharmaceuticals: 398,280 shares worth $2.25M.
  • BML Capital Management added most to Adverum Biotechnologies in Q2 2024, an estimated $10.5M increase.
  • BML Capital Management's biggest Q2 2024 reduction was Design Therapeutics, cutting an estimated $1.78M.
  • BML Capital Management fully exited Cyteir Therapeutics, Inc. Common Stock in Q2 2024, selling an estimated $11M.
  • BML Capital Management's ten largest holdings make up 84% of its $140M portfolio in Q2 2024.
  • BML Capital Management opened 3 new positions and closed 7 in Q2 2024.
  • BML Capital Management's portfolio value fell 7.6% quarter-over-quarter to $140M.

Based on BML Capital Management's 13F filing for Q2 2024, filed 7 Aug 2024.